Clinical trial / 2008
Soy isoflavone supplementation was linked to slower PSA rise in recurrent prostate cancer.
In an open-label, nonrandomized phase II trial, 20 patients with prostate-specific antigen recurrence after previous local therapy consumed soy milk containing 47 mg of isoflavones three times daily for 12 months. An estimated annual PSA increase of 56% before entry slowed to 20% during the trial (p = 0.05). Post-entry slope was significantly reduced in 6 patients, increased in 2 patients, and remained statistically unchanged in 12 patients.
- Study type
- Open-label nonrandomized phase II trial
- Who was studied
- 20 patients with rising PSA after prior local therapy
- What was measured
- Prostate-specific antigen slope and isoflavone levels
THE PAPER
Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.
Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, Rosser CJ. BMC Cancer, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.